AU2010270971B2 - Methods for treating or preventing fatigue - Google Patents

Methods for treating or preventing fatigue Download PDF

Info

Publication number
AU2010270971B2
AU2010270971B2 AU2010270971A AU2010270971A AU2010270971B2 AU 2010270971 B2 AU2010270971 B2 AU 2010270971B2 AU 2010270971 A AU2010270971 A AU 2010270971A AU 2010270971 A AU2010270971 A AU 2010270971A AU 2010270971 B2 AU2010270971 B2 AU 2010270971B2
Authority
AU
Australia
Prior art keywords
compound
carbon atoms
fatigue
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010270971A
Other languages
English (en)
Other versions
AU2010270971A1 (en
Inventor
Gary Bream
Stephen E. Butts
Moise A. Khayrallah
Susan Marie Melnick
Duncan Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2010270971A1 publication Critical patent/AU2010270971A1/en
Application granted granted Critical
Publication of AU2010270971B2 publication Critical patent/AU2010270971B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010270971A 2009-06-22 2010-06-21 Methods for treating or preventing fatigue Active AU2010270971B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (2)

Publication Number Publication Date
AU2010270971A1 AU2010270971A1 (en) 2012-01-19
AU2010270971B2 true AU2010270971B2 (en) 2015-08-20

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010270971A Active AU2010270971B2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Country Status (13)

Country Link
US (5) US8741950B2 (h)
EP (1) EP2445490B1 (h)
JP (3) JP6095366B2 (h)
KR (3) KR102021075B1 (h)
CN (2) CN102481274A (h)
AU (1) AU2010270971B2 (h)
BR (1) BRPI1015233A2 (h)
CA (1) CA2765463C (h)
IN (1) IN2012DN00624A (h)
MX (1) MX2012000034A (h)
RU (1) RU2567801C2 (h)
TW (1) TWI453014B (h)
WO (1) WO2011005473A2 (h)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI419681B (zh) 2005-06-08 2013-12-21 Sk Biopharmaceuticals Co Ltd 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
JP6095366B2 (ja) * 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
WO2011055965A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
ES2554459T3 (es) 2011-12-21 2015-12-21 Innobioscience, Llc Terapia combinada con interferón beta y andrografólidos para la esclerosis múltiple
TWI663971B (zh) 2013-03-13 2019-07-01 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
KR20210152011A (ko) * 2013-07-12 2021-12-14 에스케이바이오팜 주식회사 금연의 촉진
US9226910B2 (en) 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
PL3065751T3 (pl) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Sposób leczenia raka i chorób współistniejących
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
SG11201903076QA (en) 2016-10-06 2019-05-30 Jazz Pharmaceuticals International Iii Ltd Carbamoyl phenylalaninol compounds and uses therof
WO2018124769A1 (ko) * 2016-12-30 2018-07-05 주식회사 동진쎄미켐 코팅 조성물 및 이로부터 제조되는 필름
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US20250032442A1 (en) * 2021-11-16 2025-01-30 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
US6140532A (en) * 1995-04-10 2000-10-31 Sk Corporation O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
JP5298334B2 (ja) 2005-06-22 2013-09-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
BRPI0719275A2 (pt) 2006-10-13 2014-04-29 Janssen Pharmaceutica Nv Composições de carbamatos de fenil-alquil-amino
JP6095366B2 (ja) * 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055965A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI663971B (zh) * 2013-03-13 2019-07-01 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140532A (en) * 1995-04-10 2000-10-31 Sk Corporation O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders

Also Published As

Publication number Publication date
CA2765463C (en) 2018-10-09
US8741950B2 (en) 2014-06-03
US20120142769A1 (en) 2012-06-07
CN106727486A (zh) 2017-05-31
US20180263950A1 (en) 2018-09-20
KR102021075B1 (ko) 2019-11-04
TWI453014B (zh) 2014-09-21
EP2445490A2 (en) 2012-05-02
KR20190105675A (ko) 2019-09-17
KR102173587B1 (ko) 2020-11-04
US9999609B2 (en) 2018-06-19
JP2015214564A (ja) 2015-12-03
JP2018188450A (ja) 2018-11-29
RU2567801C2 (ru) 2015-11-10
KR20170086710A (ko) 2017-07-26
US20200061017A1 (en) 2020-02-27
CA2765463A1 (en) 2011-01-13
BRPI1015233A2 (pt) 2018-02-20
US20140243406A1 (en) 2014-08-28
RU2012101947A (ru) 2013-07-27
JP2012530779A (ja) 2012-12-06
JP6095366B2 (ja) 2017-03-15
JP6368285B2 (ja) 2018-08-01
EP2445490A4 (en) 2019-10-23
CN102481274A (zh) 2012-05-30
KR20120098578A (ko) 2012-09-05
MX2012000034A (es) 2012-02-21
EP2445490B1 (en) 2023-02-08
WO2011005473A2 (en) 2011-01-13
US10507192B2 (en) 2019-12-17
US9464041B2 (en) 2016-10-11
AU2010270971A1 (en) 2012-01-19
TW201105320A (en) 2011-02-16
US20170000756A1 (en) 2017-01-05
IN2012DN00624A (h) 2015-06-12
WO2011005473A9 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
US10507192B2 (en) Methods for treating or preventing fatigue using O-carbamoyl-phenylalaninol compounds
ES2564935T3 (es) Derivados de quinazolinona 5-sustituidos como agentes anti-cancerosos
EP2965756B1 (en) Selective ep4 receptor antagonistic substance for treatment of cancer
US9248098B2 (en) Treating or preventing pain using spicamycin derivatives
US20160279160A1 (en) Compositions comprising spicamycin derivatives and methods of use thereof
HK1234314A1 (en) Methods for treating or preventing fatigue
HK1171657A (en) Methods for treating or preventing fatigue
US20220125844A1 (en) Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy
HK40003061B (en) Selective ep4 receptor antagonistic substance for treatment of cancer
HK1214763B (en) Selective ep4 receptor antagonistic substance for treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)